8-KOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Oct 14, 2022)

Filed October 14, 2022For Securities:ONCBEIGF

Summary

This 8-K filing by BeOne Medicines Ltd. (ONC) reports two significant developments regarding their drug BRUKINSA® (zanubrutinib). First, on October 12, 2022, BeiGene announced that the Phase 3 ALPINE trial demonstrated superior Progression-Free Survival (PFS) for BRUKINSA® compared to IMBRUVICA® (ibrutinib), as assessed by both independent review committee and investigator. This outcome is a crucial indicator of the drug's efficacy in managing chronic lymphocytic leukemia (CLL). Second, on October 14, 2022, BeiGene announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the approval of BRUKINSA® for the treatment of adult patients with CLL. This positive opinion is a strong precursor to potential market approval in Europe, signifying a major regulatory milestone for the drug and expanding its commercial prospects.

Key Highlights

  • 1BeiGene announced superior Progression-Free Survival (PFS) in the Phase 3 ALPINE trial for BRUKINSA® (zanubrutinib) compared to IMBRUVICA® (ibrutinib).
  • 2The positive PFS results were confirmed by both an independent review committee (IRC) and the trial investigator.
  • 3The ALPINE trial focused on the treatment of adult patients with chronic lymphocytic leukemia (CLL).
  • 4The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for BRUKINSA® in CLL.
  • 5This CHMP opinion signifies a key regulatory step towards market access for BRUKINSA® in Europe.
  • 6The filing includes press releases detailing these advancements as exhibits.

Frequently Asked Questions

The Phase 3 ALPINE trial demonstrated that BRUKINSA® (zanubrutinib) achieved superior Progression-Free Survival (PFS) compared to IMBRUVICA® (ibrutinib) in patients with chronic lymphocytic leukemia (CLL). This indicates BRUKINSA® may be a more effective treatment option for extending the time patients remain free from disease progression.

A positive opinion from the CHMP is a strong recommendation for the European Medicines Agency (EMA) to grant marketing authorization for BRUKINSA® in the treatment of adult CLL patients. This is a critical step towards commercialization and availability of the drug in the European market.

The announcement regarding the ALPINE trial results was made on October 12, 2022, and the announcement regarding the positive CHMP opinion was made on October 14, 2022.

The key drugs mentioned are BRUKINSA® (zanubrutinib), developed by BeiGene, and IMBRUVICA® (ibrutinib), against which BRUKINSA® was compared in the trial.